Pretomanid is the third new medicine for drug-resistant tuberculosis (DR-TB) to be approved by a stringent regulatory authority in the past decade and the second drug in a class of medicines called nitroimidazoles. It was approved by the United States Food and Drug Administration in August 2019.

GDF can supply pretomanid as part of the combination regimen with bedaquiline, linezolid and moxifloxacin (e.g., the BPaLM regimen). 

For questions related to ordering pretomanid, please contact GDF at